---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-114763"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:02:40.163792+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pasithea reports Phase 1 partial response for PAS-004 in advanced cancer; ALS Association awards $1M grant

## Summary
- BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.
- Overall disease control rate 71.4% in BRAF-mutated tumors; no DLTs or discontinuations across 27 patients.
- PAS-004 tablet formulation shows 3-fold higher dose-normalized exposure vs capsule with less variability.
- Cohort 7 (37mg capsule): zero TRAEs in DLT period; 80% pERK inhibition at Cmax; SRC clears escalation to 45mg.
- ALS Association awards ~$1M grant for Phase 1 study of PAS-004 in 12 ALS patients (safety, ALSFRS-R, NfL).

## SEC filing metadata
- accession: 0001213900-25-114763
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390025114763/0001213900-25-114763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390025114763/ea0266606-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-114763
- JSON: https://secwatch.observer/filing/0001213900-25-114763.json
- Plain text: https://secwatch.observer/filing/0001213900-25-114763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.